)
)
)
PEACCEL
.jpg)
Company Description: Quantum-ready, AI-native drug-discovery platform with first-in-class anti-infective & metabolic peptides, $8.7m+ non-dilutive funding locked in, and a patent estate already battle-tested against a US major player - now ready for scale-up.
Raising funds: $50M Series A
Use:
- scale the AI + Quantum engine
- secure multiple strategic partnerships
- and advance 2 lead drug to IND-readiness.
PEACCEL is pioneering AI- and Quantum-driven peptide and protein design. Its proprietary innov’SAR™ platform integrates generative AI, reinforcement learning, and early Quantum machine learning to engineer high-value biologics with exceptional speed and precision. The company targets two major unmet medical needs: (1) antimicrobial resistance, and (2) cardio-metabolic disease through peptides entering pre-clinical development. Powered by Google Cloud and recognized by NVIDIA as an “AI Start-Up to Watch”.
PEACCEL demonstrated a quantum advantage up to 14 qubits for drug toxicity prediction.
Goal for Presentation: Fundraising: $50M Series A Use: - scale the AI + Quantum engine - secure multiple strategic partnerships - and advance 2 lead drug to IND-readiness. You want to shape the next generation of Quantum AI in Pharma: Join us!
Additional Comments:
Who referred you to this application?:
Goal for Presentation: Fundraising: $50M Series A Use: - scale the AI + Quantum engine - secure multiple strategic partnerships - and advance 2 lead drug to IND-readiness. You want to shape the next generation of Quantum AI in Pharma: Join us!
Additional Comments:
Who referred you to this application?:
What is your next catalyst (value inflection) update?
Milestones 18-24 months: 2 IND-enabling packages | 3 active platform licenses | 1 drug out-licensing | 4 paid partnerships/programs.
We reach profitability in 2027, and by 2029: • $203M revenue
Year Founded
2018
Lead Product in Development
- Quantum drug discovery platform
- The company targets two major unmet medical needs: (1) antimicrobial resistance, through first-in-class therapeutic peptides, and (2) cardio-metabolic disease, via a proprietary cholesterol-clearing peptide — both entering pre-clinical development.
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
CEO/Top Company Official
Prof. Frederic Cadet
When you expect your next catalyst update?
March 2028
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
